REG - Hellenic Dynamics - Appointment of Katherine Fleming to Advisory Board

Hellenic DynamicsAnnouncement

27/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230327:nRSa2334Ua&default-theme=true

RNS Number : 2334U  Hellenic Dynamics PLC  27 March 2023

27 March 2023

 

Hellenic Dynamics plc

("Hellenic Dynamics" or the "Company")

 

Appointment of Katherine Fleming to Advisory Board

 

London, 27 March 2023: Hellenic Dynamics plc (LSE: HELD) a medical cannabis
cultivation company, is pleased to announce the appointment of Katherine
Fleming to its Advisory Board. Katherine is currently the President and CEO of
the J. Paul Getty Trust, the international cultural and philanthropic
institution, overseeing its 1,500 employees and US$8.5 billion endowment fund.

 

Katherine previously held the position of Provost and Professor of History of
New York University, the largest private university in the United States by
enrolment, where she is also the Alexander S. Onassis Chair of Hellenic
Studies. As Provost, she oversaw the University's global academic strategy and
was responsible for budgetary allocation. Past international appointments have
included serving as President of the Board of the University of Piraeus,
Greece and as associate member of the faculty of the École Normale
Supérieure in Paris, France.

 

Katherine holds a number of honours including being named to the French
Légion d'Honneur and being decorated by the Greek Government as a commander
in the Order of Beneficence. In 2016 Katherine was recognized for her
contributions to Greek culture by being granted honorary Greek citizenship.

 

Katherine will assist Hellenic Dynamics both domestically in Greece with her
strong and well-established relationships, as well as on the international
stage as it aims to be the dominant supplier of THC medical cannabis products
in Europe.

 

Hellenic Dynamics is a medical cannabis cultivator specifically focused on the
cultivation and supply of tetrahydrocannabinol ("THC") dominant strains of
medical cannabis flowers destined for the rapidly growing medical cannabis
markets across Europe. In December 2022, Hellenic Dynamics became the first
medical cannabis cultivator to list on the London Stock Exchange's main market
for listed securities.

 

Davinder Rai, CEO of Hellenic Dynamics, commented:

"We are honoured to have Katherine join our Advisory Board and I personally
look forward to working with her. Katherine brings a huge breadth of
experience that will benefit Hellenic both domestically in Greece and in wider
Europe."

 

Katherine Fleming, commented:

"I'm delighted to join Hellenic Dynamics, which connects two worlds about
which I care deeply: patients for whom medical cannabis can improve their
quality of life and outcomes, and Greece - a country with massive potential
for being the leader in the European medical cannabis cultivation space."

 

Enquires:

 

Hellenic Dynamics plc                               +44 (0)20
3818 7850

Davinder Rai
 davinder@hellenicdynamics.com

 

Cairn Financial Advisers LLP

Emily Staples / Jo Turner                           +44 (0)20
7213 0880

 

Peterhouse Capital

Lucy Williams / Charles Goodfellow            +44 (0)20 7469 0930

 

J&H Communications

George Hudson                                         +44
(0)7803 603130

About Hellenic Dynamics plc

Founded in 2019, Hellenic Dynamics is specifically focused on the cultivation
and supply of THC ("tetrahydrocannabinol") - dominant strains of medical
cannabis flowers, destined for the growing medical cannabis markets across
Europe. Hellenic Dynamics' core strategy is to develop and operate its 40,000
square metre active cultivation licence from its 195,506 square metre facility
located near Thessaloniki in Northern Greece. In full production, Hellenic
Dynamics is capable of producing over 54,000 kg of dried flowers per annum.

Hellenic Dynamics will take advantage of its relatively low cost base
resulting from a comparatively low cost of power, having its own running water
supply and the labour rates for skilled and semi-skilled labour in Northern
Greece.

25 European countries now allow medical cannabis via prescription and the
European cannabis market is expected to reach €43.3 billion per annum by
2027. Sales of Hellenic Dynamics' dried THC-dominant cannabis flowers and
extracts are initially intended for export into Europe's largest market -
Germany, in addition to other European markets including domestically in
Greece.

As the first medical cannabis cultivator to obtain a listing on the main
market for listed securities of the London Stock Exchange, Hellenic is
significantly different to the number of CBD (Cannabidiol) related companies
that have appeared over the recent years. Hellenic Dynamics cultivates
THC-dominant medical cannabis flowers. THC-dominant medical cannabis products
are only available via a medical prescription. Medicinal cannabis has been
approved for use both in the United Kingdom and Germany, plus 23 other
European countries, for conditions including but not limited to  chronic
pain, intractable chemotherapy-related nausea, anxiety, insomnia, Tourette's
syndrome, substance use disorder, multiple sclerosis, IBS, spinal cord
treatment, lack of appetite due to HIV/AIDS, cachexia, anorexia and glaucoma.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZGZFGVVGFZZ